Clinical analysis of telmisartan for metabolic syndrome

Abstract

Objective To investigate the influence and safety of telmisartan on blood pressure, metabolic disorders of glucose and lipid, inflammatory factors, serum uric acid(UA) and microalbuminuria(mALB) in patients with metabolic syndrome(MS). Methods Eighty-five MS patients were enrolled and divided into the telmisartan group with telmisartan 40 mg/d and the life style-intervented group, for 6 months continuously. The levels of blood pressure, blood glucose, fasting insulin(FINS), insulin resistance index(HOMA-IR), blood lipid, high sensitive C-reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), UA, urine albumin excretionrate(UAER), hepatic and renal functions, creatine kinase(CK) were determined for both groups before and after treatment. Results In the telmisartan group, systolic blood pressure(SBP), diastolic blood pressure(DBP), fasting plasma glucose(FPG), 2 h postprandial blood glucose(2hPG), FINS, HOMA-IR, hs-CRP TNF-α, IL-6, UA and UAER were significantly decreased compared with pretreatment(P 0.05). After 6 months hs-CRP, TNF-α, IL-6, UA and UAER were also slightly reduced, but difference was not significant(P>0.05). SBP, DBP, FPG, 2 hPG, FINS, HOMA-IR, hs-CRP, TNF-α, IL-6, UA and UAER in the telmisartan group were significant lower than those in life style-intervented group after 6 months follow-up(P<0.05). Conclusions Telmisartan can not only improve blood pressure, metabolic disorders of blood glucose and lipid, improve insulin resistance, but also can inhibit inflammation in MS patients and reduce the levels of UA and UAER. It does not cause serious adverse events, and its security is good. Key words: Telmisartan; Metabolic syndrome; Insulin resistance; Inflammatory factors